InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,855.20
(
0.04%
)
Dow Jones
39,375.87
(
0.00%
)
Brent Oil
85.74
(
-0.89%
)
Bitcoin
57,110.98
(
2.26%
)
Post# of 252506
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

rfj1862

Send PM Follow Ignore
Followers 39
Posts 1714
Boards Moderated 0
Alias Born 10/05/2005

rfj1862

Re: drbio45 post# 48864

Saturday, 06/23/2007 12:54:34 PM

Saturday, June 23, 2007 12:54:34 PM

Post# of 252506
>Valuation wise which one is cheaper<

XNPT: 1) The RLS market is a bigger opportunity than developing yet another drug for PHN; 2) Remember that they have a baclofen analog in development as well; this is a potential billion-dollar drug.

I own neither, but I did own XNPT.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up